DXCM - Dexcom Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Company Name, Ticker, Industry, else..

Extremely challenging financial reporting period for ACTG in the most recent fiscal period

For the fiscal time-frame closing December 31 2022 ACTG slipped into shortfall of $-0.37 per share compare to $1.06 a year before and EPS fell from $0.02 per share from the previous financial reporting period.

Sales dropped sharply by -79.259 % to $13.12 millions from $63.26 millions in the corresponding financial reporting period a year before and sequentially Sales fell by -17.364 % from $15.88 millions.

Akero Therapeutics Inc added some good surprise for the stock market, exhibiting a significant growth in fourth quarter of 2022 earnings season with operating deficit of $-25.42 millions

The Major Pharmaceutical Preparations industry experts begin to scrutinize the fourth quarter of 2022 performance. Presently they follow operating deficit of $-25.42 millions, from the Akero Therapeutics Inc , which has not cited any revenue still, for the respective October to December 31 2022 reporting season.

Severe hit for the company in the fourth quarter of 2022

For the fiscal period closing December 31 2022 company income per share dropped by -30.1 % of $0.30 per share compare to $0.42 a year prior and income per share turned positive from $-0.12 per share from the prior quarter.

Sales went down sharply by -79.217 % to $306.38 millions from $1.47 billions in the same quarter a year prior and sequentially Sales surged by 83.87 % from $166.63 millions.

Critical quarter for MKFG during the October to December 31 2022 period

For the October to December 31 2022 interval MKFG lost money of $-0.05 per share compare to $-0.05 a year ago and earnings per share improved from $-0.12 per share from the preceding quarter.

Sales dropped sharply by -55.841 % to $29.66 millions from $67.18 millions in the similar quarter a year ago and sequentially Sales improved by 17.677 % from $25.21 millions.

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071

DXCM Company Profile

Extremely challenging financial reporting period for ACTG in the most recent fiscal period

The company reported a -4.129 %, reduction in Sales, amid the most recent fiscal period

Akero Therapeutics Inc added some good surprise for the stock market, exhibiting a significant growth in fourth quarter of 2022 earnings season with operating deficit of $-25.42 millions

Severe hit for the company in the fourth quarter of 2022

Critical quarter for MKFG during the October to December 31 2022 period


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar FRST's Profile Stock Price FRST's Financials Business Description Fundamentals Charts & Quotes FRST's News Suppliers FRST's Competitors Customers & Markets Economic Indicators FRST's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness